Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance

By F. Martins, Latifyan Sofiya, Gerasimos P. Sykiotis, F. Lamine, M. Maillard, M. Fraga, K. Shabafrouz, C. Ribi, A. Cairoli, Y. Guex-Crosier and 7 more. Nature Reviews Clinical Oncology, 2019

1,924 citations recorded by the source corpus.

Subfields: Oncology

View Paper: https://www.semanticscholar.org/paper/4444f1f8850c86d3cb026b248b8d2d27a2e816c0

Citations in the corpus

• Dietary tryptophan metabolite released by intratumoral Lactobacillus reuteri facilitates immune checkpoint inhibitor treatment (2023, neutral): “Given that ICIs can induce autoimmune responses, 61 it is possible that ICI-induced autoimmune events may be further aggravated by Lr intake and/or increased dietary Trp in genetically predisposed individuals.”